#ajanta pharma products
Ajanta pharma products
AJP:Natl India Stock Quote – Ajanta Pharma Ltd
BRIDGEWATER, N.J. May 9, 2014 /PRNewswire/ — Ajanta Pharma USA Inc. a wholly owned subsidiary of Ltd, announced today the launch of Risperidone Tablets (0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg), the generic version of Risperdal®. Risperidone Tablets are used to treat schizophrenia and bipolar disorder. According to IMS Health, sales of branded and generic products totalled approximately 7 million for the 12 months ending March 2014.
Ajanta Pharma’s launch of Risperidone Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, two ANDAs have been approved with another 21 ANDAs pending US Food and Drug Administration approval.
About Ajanta PharmaAjanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 4,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology.
1] Risperdal is a registered trademark of Janssen Pharmaceuticals  IMS Health, National Sales Perspectives, March 2014
Ajanta Pharma Products – Zafax Pharma
In need of subject matter experts for your story? and find the sources you need. LEARN MORE
Loading. Select Portfolio and Asset Combination for Display on Market BandSelect PortfolioSelect Asset ClassStocksMFETFShow MoreDrag according to your convenienceET NOW RADIOET NOWTIMES NOWSummary
451.501.15-1.05-5.781.67-3.35418.91711.32Top Loser for the period amongst the peersTop Gainer for the period amongst the peersView Details:Ajanta Pharma Ltd Financial Comparisonwith peersManagement EfficiencyAjanta Pharma Ltd Peer AveragePeer RangeTrendReturn On Equity (%)36.835.30-224.1173.80Return On Assets (%)28.505.52-40.3545.52Return On Capital Employed (%)38.2210.40-55.6557.06Fixed Assets Turnover (x)1.851.140.263.41Profitability & GrowthGross Profit Margin (%)30.638.45-65.6433.04Operating Profit Margin (%)34.1213.86-34.1037.40Net Profit Margin (%)20.924.44-163.8970.66Financial StrengthLiquidityQuick Ratio (x)1.852.110.4419.24Current Ratio (x)2.472.830.5721.19Cash Ratio (x)0.540.350.015.47SolvencyDebt Equity Ratio (x)0.040.680.007.57Coverage RatiosCash Flows to Long Term Debt (x)0.1410.680.00222.81Ajanta Pharma Ltd Share HoldingCategoryNo. of SharesPercentagePromoters64,929,75973.78GeneralPublic11,206,50912.73ForeignInstitutions8,587,0329.76NBanksMutualFunds1,660,6421.89Others1,597,4021.82FinancialInstitutions19,9060.02About Ajanta Pharma Ltd.Ajanta Pharma Ltd. incorporated in the year 1979, is a Large Cap company (having a market cap of Rs 12,975.02 Cr.) operating in Pharmaceuticals and health care sector.
Ajanta Pharma Ltd. key Products/Revenue Segments include Tablets which contributed Rs 760.42 Cr to Sales Value (55.59% of Total Sales), Liquids which contributed Rs 207.07 Cr to Sales Value (15.13% of Total Sales), Capsules which contributed Rs 153.91 Cr to Sales Value (11.25% of Total Sales), Ointments which contributed Rs 136.77 Cr to Sales Value (9.99% of Total Sales), Powder which contributed Rs 39.35 Cr to Sales Value (2.87% of Total Sales), Injectibles which contributed Rs 29.42 Cr to Sales Value (2.15% of Total Sales), Export Incentives which contributed Rs 25.48 Cr to Sales Value (1.86% of Total Sales), Others which contributed Rs 13.33 Cr to Sales Value (0.97% of Total Sales), Other Operating Revenue which contributed Rs 2.10 Cr to Sales Value (0.15% of Total Sales), for the year ending 31-Mar-2015.
For the quarter ended 31-Mar-2016, the company has reported a Consolidate sales of Rs. 419.20 Cr. down -9.99% from last quarter Sales of Rs. 465.71 Cr. and up 14.64% from last year same quarter Sales of Rs. 365.67 Cr. Company has reported net profit after tax of Rs. 106.31 Cr. in latest quarter.
Ajanta Pharma. We sell original legal steroids in USA at
The company’s management includes Dr.Anil Kumar, Dr.Anjana Grewal, Mr.Arvind Agrawal, Mr.Chandrakant M Khetan, Mr.Gaurang Shah, Mr.K H Viswanathan, Mr.Madhusudan B Agrawal, Mr.Mannalal B Agrawal, Mr.P R Dalal, Mr.Purushottam B Agrawal, Mr.Rajesh M Agrawal, Mr.Yogesh M Agrawal, Mr.Gaurang Shah.
Company has Kapoor & Parekh Associates as its auditors. As on 31-Mar-2016, the company has a total of 88,001,250 shares outstanding.
Date Sources:Live BSE and NSE Quotes Service: TickerPlant | Corporate Data, F
/* 728×90, создано 05.02.11 */
google_ad_slot = “6127977750”;
google_ad_width = 670;
google_ad_height = 90;